[go: up one dir, main page]

ME03078B - Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina - Google Patents

Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina

Info

Publication number
ME03078B
ME03078B MEP-2018-154A MEP2018154A ME03078B ME 03078 B ME03078 B ME 03078B ME P2018154 A MEP2018154 A ME P2018154A ME 03078 B ME03078 B ME 03078B
Authority
ME
Montenegro
Prior art keywords
prokineticine
sulfonylpiperidine
derivatives
treatment
mediated diseases
Prior art date
Application number
MEP-2018-154A
Other languages
German (de)
English (en)
French (fr)
Inventor
Colm Carroll
Anne Goldby
Martin Teall
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ME03078B publication Critical patent/ME03078B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2018-154A 2012-05-30 2013-05-29 Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina ME03078B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201209587A GB201209587D0 (en) 2012-05-30 2012-05-30 Therapeutic compounds
PCT/GB2013/051415 WO2013179024A1 (en) 2012-05-30 2013-05-29 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
EP13728238.0A EP2855449B1 (en) 2012-05-30 2013-05-29 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases

Publications (1)

Publication Number Publication Date
ME03078B true ME03078B (me) 2019-01-20

Family

ID=46546171

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-154A ME03078B (me) 2012-05-30 2013-05-29 Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina

Country Status (25)

Country Link
US (6) US9475795B2 (me)
EP (1) EP2855449B1 (me)
JP (1) JP6177896B2 (me)
CN (1) CN104520292B (me)
AR (1) AR091208A1 (me)
CA (1) CA2873850C (me)
CY (1) CY1120420T1 (me)
DK (1) DK2855449T3 (me)
ES (1) ES2671629T3 (me)
GB (1) GB201209587D0 (me)
HK (1) HK1208675A1 (me)
HR (1) HRP20180729T1 (me)
HU (1) HUE037673T2 (me)
LT (1) LT2855449T (me)
ME (1) ME03078B (me)
NO (1) NO2855449T3 (me)
PL (1) PL2855449T3 (me)
PT (1) PT2855449T (me)
RS (1) RS57329B1 (me)
SI (1) SI2855449T1 (me)
SM (1) SMT201800274T1 (me)
TR (1) TR201807666T4 (me)
TW (1) TWI612041B (me)
UY (1) UY34835A (me)
WO (1) WO2013179024A1 (me)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
EP3010900B1 (en) * 2013-06-21 2018-01-03 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
GB201420095D0 (en) 2014-11-12 2014-12-24 Takeda Pharmaceutical New use
CN106699635B (zh) * 2015-11-12 2019-10-22 北京福元医药股份有限公司 一种制备Delamanid中间体的方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
HUE061584T2 (hu) 2018-03-22 2023-07-28 Hoffmann La Roche Oxazin-monoacil-glicerol-lipáz (MAGL) gátlók
PT3837263T (pt) 2018-08-13 2024-08-30 Hoffmann La Roche Novos compostos heterocíclicos enquanto inibidores da monoacilglicerol lípase
KR20220062515A (ko) 2019-09-12 2022-05-17 에프. 호프만-라 로슈 아게 Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물
EP4208456A1 (en) 2020-09-03 2023-07-12 F. Hoffmann-La Roche AG Heterocyclic compounds
CN115974785A (zh) * 2022-12-09 2023-04-18 南京先进生物材料与过程装备研究院有限公司 一种3,5-二取代吡唑类化合物的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902814A (en) 1994-08-24 1999-05-11 Astra Ab Spiro-Azabicyclic Compounds useful in therapy
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US20030232860A1 (en) 2000-07-18 2003-12-18 Hironori Harada Medicine comprising dicyanopyridine derivative
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
NZ539828A (en) 2001-05-18 2007-01-26 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ES2280538T3 (es) 2001-06-01 2007-09-16 Astrazeneca Ab Nuevo ligando para receptores nicotinicos de acetilcolina utiles en terapia.
EP1676844A1 (en) * 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
CN1325500C (zh) 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 呋喃基化合物
US7186836B2 (en) 2002-04-18 2007-03-06 Astrazeneca Ab Thienyl compounds
ATE433981T1 (de) 2002-04-18 2009-07-15 Astrazeneca Ab Heterocyclische verbindungen
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
BR0315166A (pt) * 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
AU2003274551A1 (en) 2002-11-12 2004-06-03 Pfizer Products Inc. Quinoline derivatives
CA2516234A1 (en) 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
WO2005016910A1 (ja) 2003-08-18 2005-02-24 Sankio Chemical Co., Ltd. ピリジルテトラヒドロピリジン類およびピリジルピペリジン類とそれらの製造方法
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2560346A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
AR058406A1 (es) 2005-12-29 2008-01-30 Janssen Pharmaceutica Nv Antagonistas del receptor de proquineticina 1
CN101405002A (zh) 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008130718A1 (en) * 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
US8722896B2 (en) 2008-12-17 2014-05-13 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
WO2010114909A1 (en) * 2009-03-31 2010-10-07 Vanderbilt University Sulfonyl-piperidin-4-yl methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
GB201209587D0 (en) * 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds

Also Published As

Publication number Publication date
US20160376256A1 (en) 2016-12-29
US10167273B2 (en) 2019-01-01
TR201807666T4 (tr) 2018-06-21
SMT201800274T1 (it) 2018-07-17
US9475795B2 (en) 2016-10-25
LT2855449T (lt) 2018-05-25
JP6177896B2 (ja) 2017-08-09
HK1208675A1 (en) 2016-03-11
CN104520292A (zh) 2015-04-15
US20190084962A1 (en) 2019-03-21
US20150111922A1 (en) 2015-04-23
AR091208A1 (es) 2015-01-21
HUE037673T2 (hu) 2018-09-28
CY1120420T1 (el) 2019-07-10
TWI612041B (zh) 2018-01-21
US10544126B2 (en) 2020-01-28
JP2015519357A (ja) 2015-07-09
ES2671629T3 (es) 2018-06-07
NO2855449T3 (me) 2018-08-04
US12054474B2 (en) 2024-08-06
GB201209587D0 (en) 2012-07-11
CA2873850A1 (en) 2013-12-05
SI2855449T1 (en) 2018-07-31
PL2855449T3 (pl) 2019-01-31
TW201400473A (zh) 2014-01-01
WO2013179024A1 (en) 2013-12-05
US11512066B2 (en) 2022-11-29
EP2855449B1 (en) 2018-03-07
EP2855449A1 (en) 2015-04-08
HRP20180729T1 (hr) 2018-07-27
US20130324576A1 (en) 2013-12-05
PT2855449T (pt) 2018-06-08
RS57329B1 (sr) 2018-08-31
CN104520292B (zh) 2016-09-14
DK2855449T3 (en) 2018-06-06
UY34835A (es) 2013-12-31
CA2873850C (en) 2016-10-04
US20230073334A1 (en) 2023-03-09
US20200190059A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
FR19C1062I2 (fr) Derives macrocycliques pour le traitement de maladies proliferatives
ME03078B (me) Derivati sulfonil piperidina i njihova upotreba za lečenje bolesti posredovanih preko prokineтicina
EP2931268A4 (en) GAMMA HYDROXYBUTYRATE COMPOSITIONS AND USE FOR THE TREATMENT OF DISORDERS
EP2709672A4 (en) COMPOSITIONS AND METHODS FOR TREATING NETWORK GLAND DISEASES
EP2872151A4 (en) AZELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT / PREVENTION OF AUTOIMMUNE DISEASES
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2818483A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2909209A4 (en) 2'-CYAN-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP3004083A4 (en) COMPOUNDS FOR THE TREATMENT OF DRUG-RESISTANT AND PERSISTENT TUBERCULOSIS
EP2948479A4 (en) INVESTIGATION AND TREATMENT OF BRADYKININ-MEDIATED DISEASES
EP2877184A4 (en) COMPOSITIONS AND TREATMENT PROCEDURES FOR EYE DISEASES AND DISORDERS
EP2830661A4 (en) DIAGNOSTIC METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2773342A4 (en) COMPOSITIONS FOR THE TREATMENT OF VIRUS DISEASES
EP2970099A4 (en) SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF EYE DISEASES AND DRESSES
EP2983791A4 (en) METHOD AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP3025716A4 (en) SUBSTANCE FOR TREATING OR TREATING PAIN
EP2914274A4 (en) GENETICALLY MODIFIED PROBIOTIC FOR THE TREATMENT OF PHENYLKETONURIA
EP2919788A4 (en) METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
EP2623494A4 (en) MEDICINE FOR THE TREATMENT OF EYE DISEASES
EP2968321A4 (en) COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP2967062A4 (en) DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION
EP2753365A4 (en) MEDICINE AND METHODS OF TREATING INFLAMMATORY SUDDEN AND DISEASES